Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Microbiome, Metabolome, Smoking history
Brief summary
The goal of this observational registry study is to compare characteristics of gut and sputum microbiome and metabolome among COPD patients with significant smoking history, COPD patients without significant smoking history and healthy smoker. Additionally, the investigators investigate the difference of blood metabolites and peripheral blood mononuclear cells level among groups. The main questions it aims to answer are: * Are there significant difference in fecal or sputum microbiome and metabolome between COPD patients and healthy smoker? * Are there any distinct characteristics in microbiome and metabolome in COPD with COPD patients with significant smoking history, COPD patients without significant smoking history compared with healthy smoker? * Are there any difference in blood metabolites and peripheral blood mononuclear cells levels among patients with significant smoking history, COPD patients without significant smoking history and healthy smoker * Might distinct characteristics of microbiome and metabolites in COPD patients be related to worse clinical outcomes in COPD patients?
Interventions
None listed
Sponsors
Seoul National University College of Medicine
HEM Pharma Inc.
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* COPD Patients, defined by FEV1/FVC \<0.7, who * agree with informed consent * have no history of acute exacerbation within 3 months * Healthy smoker without airflow limitation, defined by FEV1/FVC ≥0.7, who * have smoking history with at least 30 pack-year * agree with informed consent * do not use medication for chronic respiratory disease
Exclusion criteria
* Withdrawal of informed consent * History of acute exacerbation or antibiotics use within 3 months * Difficulty to collect adequate stool, sputum and blood samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| secondary bile acid level | At enrollment | the investigators will compare the secondary bile acid level among groups |
| Butyric acid level | At enrollment | the investigators will compare the butyric acid level among groups |
| Isovaleric acid level | At enrollment | the investigators will compare the Isovaleric acid level among groups |
| Valeric acid level | At enrollment | the investigators will compare the valeric acid level among groups |
| dimethylglycine level | At enrollment | the investigators will compare the dimethylglycine level among groups |
| Shannon diversity index | At enrollment | the investigators will compare alpha diversity and community similarity among groups by using the Shannon diversity index. |
| Simpson index | At enrollment | the investigators will compare alpha diversity and community similarity among groups by using the Simpson index. |
| Principal component analysis | At enrollment | the investigators will compare beta diversity and community similarity among groups by using the principal component analysis. |
| Microbiome composition by metagenomic analysis | At enrollment | The composition of microbiome will be presented as bar graph. |
| Peripheral blood mononuclear cells level | At enrollment | the investigators will compare the Peripheral blood mononuclear cells level among groups |
| Acetic acid level | At enrollment | the investigators will compare the acetic acid level among groups |
| Propionic acid level | At enrollment | the investigators will compare the Propionic acid level among groups |
| Isobutyric acid level | At enrollment | the investigators will compare the Isobutyric acid level among groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference of metabolome according to Exacerbation | within 1 year after enrollment | the investigators will investigate the baseline difference of metabolome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation |
| Difference of microbiome according to death | within 1 year after enrollment | the investigators will investigate the baseline difference of microbiome between COPD patients with death and COPD patients without death |
| Difference of metabolome according to death | within 1 year after enrollment | the investigators will investigate the baseline difference of metabolome between COPD patients with death and COPD patients without death |
| Difference of microbiome according to Exacerbation | within 1 year after enrollment | the investigators will investigate the baseline difference of microbiome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation |
Outcome results
None listed